Autori: Stanchev Atanas
| Naslov | Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study) (Meeting Abstract) |
| Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Boskovic Darinka V Griskevicius Laimonas Lejniece Sandra Spasov Emil Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Stanchev Atanas Kwakkelstein Martin Ulmer Hanno Gastl Guenther A |
| Info | BLOOD, (2007), vol. 110 br. 11, str. 317A-317A |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
